Track topics on Twitter Track topics that are important to you
The original base protocol (V501-018)(NCT00092547) was extended in amendments 05 and 06 to provide 37 months of follow-up. Additionally, subjects in the Placebo Group during the base study were given 3 doses of open-label GARDASIL™ (V501) at Months 30, 32, and 36.
The study was extended again in amendment V501-018-10(NCT00092547) to allow a follow-up period to Month 126.
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Healthy Papillomavirus Infections
V501, Comparator: Placebo, V501
Active, not recruiting
Published on BioPortfolio: 2014-08-27T03:54:03-0400
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
This study is to assess the tolerability and efficacy of a vaccine being evaluated to reduce the incidence of human papillomavirus (HPV) infection and disease (external genital warts and v...
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
This is a study of V501 [quadrivalent Human Papillomavirus (HPV) (Type 6, 11, 16 and 18) L1 Virus-Like Particle (VLP) vaccine] in healthy Japanese boys. This study will consist of two peri...
A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects.
To evaluate the analgesic/antihyperalgesic effect of ASP8477.
To assess the consistency between human papillomavirus (HPV) mRNA testing in women with a history of previous HPV infections diagnosed by HPV DNA assay and the potential effects on follow-up HPV scree...
Our ability to detect statistical dependencies between different events in the environment is strongly biased by the number of coincidences between them. Even when there is no true covariation between...
To monitor the changes in prevalence of human papillomavirus (HPV) infections in women
Due to recent technical improvements and some encouraging new results, there has been a resurgence of interest in the possibility that a substantial proportion of breast cancers (BCs) may be caused by...
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
ONCOGENE PROTEINS from papillomavirus that deregulate the CELL CYCLE of infected cells and lead to NEOPLASTIC CELL TRANSFORMATION. Papillomavirus E7 proteins have been shown to interact with various regulators of the cell cycle including RETINOBLASTOMA PROTEIN and certain cyclin-dependent kinase inhibitors.
A type of XIPAPILLOMAVIRUS causing alimentary carcinoma in cattle. It is related to Bovine papillomavirus 3.
A type of human papillomavirus especially associated with malignant tumors of the genital and RESPIRATORY MUCOSA.
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...